S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:LHDX

Lucira Health - LHDX Stock Forecast, Price & News

$0.39
-0.02 (-4.85%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.36
$0.41
50-Day Range
$0.11
$0.60
52-Week Range
$0.11
$5.67
Volume
2.03 million shs
Average Volume
14.96 million shs
Market Capitalization
$15.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Lucira Health MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Lucira Health in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$20,945 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.49) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

686th out of 1,053 stocks

Diagnostic Substances Industry

9th out of 17 stocks


LHDX stock logo

About Lucira Health (NASDAQ:LHDX) Stock

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Receive LHDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter.

LHDX Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Lucira Health Slide Continues
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
See More Headlines
Receive LHDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter.

LHDX Company Calendar

Last Earnings
11/14/2022
Today
2/01/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LHDX
Fax
N/A
Employees
114
Year Founded
N/A

Profitability

Net Income
$-64,830,000.00
Pretax Margin
-67.53%

Debt

Sales & Book Value

Annual Sales
$93.06 million
Book Value
$4.81 per share

Miscellaneous

Free Float
27,914,000
Market Cap
$15.73 million
Optionable
Not Optionable
Beta
2.07

Key Executives

  • Mr. Erik T. Engelson (Age 62)
    Pres, CEO & Director
    Comp: $1.05M
  • Mr. Kevin Walter Collins (Age 45)
    Chief Revenue Officer
    Comp: $740.75k
  • Mr. Ghazi Kashmolah (Age 61)
    Chief Quality Officer & Exec. VP of Regulatory Affairs
    Comp: $603.47k
  • Mr. Richard Clavano Narido
    Chief Financial Officer
  • Mr. Tony Allen (Age 59)
    Chief Operations Officer
  • Greg Chodaczek
    Investor Relations
  • Dr. Nadine Greiner Ph.D.
    Chief HR Officer













LHDX Stock - Frequently Asked Questions

Should I buy or sell Lucira Health stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucira Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LHDX shares.
View LHDX analyst ratings
or view top-rated stocks.

How have LHDX shares performed in 2023?

Lucira Health's stock was trading at $0.1111 on January 1st, 2023. Since then, LHDX shares have increased by 253.0% and is now trading at $0.3922.
View the best growth stocks for 2023 here
.

Are investors shorting Lucira Health?

Lucira Health saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 2,165.9% from the December 31st total of 53,400 shares. Based on an average trading volume of 4,880,000 shares, the short-interest ratio is presently 0.2 days. Currently, 4.0% of the company's shares are sold short.
View Lucira Health's Short Interest
.

When is Lucira Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our LHDX earnings forecast
.

How were Lucira Health's earnings last quarter?

Lucira Health, Inc. (NASDAQ:LHDX) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). The company earned $34.39 million during the quarter, compared to the consensus estimate of $33.30 million. Lucira Health had a negative trailing twelve-month return on equity of 13.55% and a negative net margin of 67.54%.

When did Lucira Health IPO?

(LHDX) raised $125 million in an initial public offering on Friday, February 5th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities, William Blair and LifeSci Capital acted as the underwriters for the IPO.

What is Lucira Health's stock symbol?

Lucira Health trades on the NASDAQ under the ticker symbol "LHDX."

Who are Lucira Health's major shareholders?

Lucira Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony Joseph Allen, Dan George, Debkishore Mitra, Epiq Capital Group, Llc, Erik T Engelson, Ghazi Kashmolah, Kevin Walter Collins and Tamanna Prashar.
View institutional ownership trends
.

How do I buy shares of Lucira Health?

Shares of LHDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucira Health's stock price today?

One share of LHDX stock can currently be purchased for approximately $0.39.

How much money does Lucira Health make?

Lucira Health (NASDAQ:LHDX) has a market capitalization of $15.73 million and generates $93.06 million in revenue each year. The company earns $-64,830,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

How many employees does Lucira Health have?

The company employs 114 workers across the globe.

How can I contact Lucira Health?

Lucira Health's mailing address is 1412 62ND STREET, EMERYVILLE CA, 94608. The official website for the company is www.lucirahealth.com. The company can be reached via phone at 510-350-8071.

This page (NASDAQ:LHDX) was last updated on 2/2/2023 by MarketBeat.com Staff